Addition of Partial Envelope Domain II into Envelope Domain III of Dengue Virus Antigen Potentiates the Induction of Virus-Neutralizing Antibodies and Induces Protective Immunity

Overview

Journal Vaccines (Basel)

Date 2020 Feb 21

PMID 32075300

Citations 5

Authors

Jisang Park

Hyun-Young Lee

Ly Tuan Khai

Nguyen Thi Thu Thuy

Le Quynh Mai

Yong-Suk Jang

Affiliations

Soon will be listed here.

Abstract

Dengue virus (DENV) comprises four serotypes in the family and is a causative agent of dengue-related diseases, including dengue fever. Dengue fever is generally a self-limited febrile illness. However, secondary infection of patients with a suboptimal antibody (Ab) response provokes life-threatening severe dengue hemorrhagic fever or dengue shock syndrome. To develop a potent candidate subunit vaccine against DENV infection, we developed the EDII-cEDIII antigen, which contains partial envelope domain II (EDII) including the fusion loop and BC loop epitopes together with consensus envelope domain III (cEDIII) of all four serotypes of DENV. We purified Ab from mice after immunization with EDII-cEDIII or cEDIII and compared their virus neutralization and Ab-dependent enhancement of DENV infection. Anti-EDII-cEDIII Ab showed stronger neutralizing activity and lower Ab-dependent peak enhancement of DENV infection compared with anti-cEDIII Ab. Following injection of Ab-treated DENV into AG129 mice, anti-EDII-cEDIII Ab ameliorated DENV infection in tissues with primary and secondary infection more effectively than anti-cEDIII Ab. In addition, anti-EDII-cEDIII Ab protected against DENV1, 2, and 4 challenge. We conclude that EDII-cEDIII induces neutralizing and protective Abs, and thus, shows promise as a candidate subunit vaccine for DENV infection.

Citing Articles

Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus.

Kim J, Lim T, Park J, Jang Y J Microbiol. 2023; 61(1):131-143.

PMID: 36723792 PMC: 9890423. DOI: 10.1007/s12275-023-00021-z.

Enzymatic bioconversion of ginseng powder increases the content of minor ginsenosides and potentiates immunostimulatory activity.

Park J, Kim J, Ko E, Jeong J, Park C, Seo J J Ginseng Res. 2022; 46(2):304-314.

PMID: 35509827 PMC: 9058844. DOI: 10.1016/j.jgr.2021.12.005.

Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice.

Ponndorf D, Meshcheriakova Y, Thuenemann E, Dobon Alonso A, Overman R, Holton N Plant Biotechnol J. 2020; 19(4):745-756.

PMID: 33099859 PMC: 8051607. DOI: 10.1111/pbi.13501.

Dengue mouse models for evaluating pathogenesis and countermeasures.

Chen R, Diamond M Curr Opin Virol. 2020; 43:50-58.

PMID: 32950933 PMC: 7774505. DOI: 10.1016/j.coviro.2020.09.001.

Current Flavivirus Research Important for Vaccine Development.

Geerling E, Steffen T, Brien J, Pinto A Vaccines (Basel). 2020; 8(3).

PMID: 32867038 PMC: 7563144. DOI: 10.3390/vaccines8030477.

References

Schoggins J, Dorner M, Feulner M, Imanaka N, Murphy M, Ploss A . Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci U S A. 2012; 109(36):14610-5. PMC: 3437900. DOI: 10.1073/pnas.1212379109. View

Villar L, Dayan G, Arredondo-Garcia J, Rivera D, Cunha R, Deseda C . Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med. 2014; 372(2):113-23. DOI: 10.1056/NEJMoa1411037. View

Oscherwitz J . The promise and challenge of epitope-focused vaccines. Hum Vaccin Immunother. 2016; 12(8):2113-2116. PMC: 4994726. DOI: 10.1080/21645515.2016.1160977. View

Bal J, Jung H, Nguyen L, Park J, Jang Y, Kim D . Evaluation of cell-surface displayed synthetic consensus dengue EDIII cells as a potent oral vaccine candidate. Microb Cell Fact. 2018; 17(1):146. PMC: 6138890. DOI: 10.1186/s12934-018-0994-8. View

St John A, Abraham S, Gubler D . Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis. Nat Rev Microbiol. 2013; 11(6):420-6. DOI: 10.1038/nrmicro3030. View

Chen Y, Maguire T, Hileman R, Fromm J, Esko J, Linhardt R . Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997; 3(8):866-71. DOI: 10.1038/nm0897-866. View

Pokidysheva E, Zhang Y, Battisti A, Bator-Kelly C, Chipman P, Xiao C . Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell. 2006; 124(3):485-93. DOI: 10.1016/j.cell.2005.11.042. View

Messina J, Brady O, Golding N, Kraemer M, Wint G, Ray S . The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019; 4(9):1508-1515. PMC: 6784886. DOI: 10.1038/s41564-019-0476-8. View

Silveira G, Wowk P, Cataneo A, Dos Santos P, Delgobo M, Stimamiglio M . Human T Lymphocytes Are Permissive for Dengue Virus Replication. J Virol. 2018; 92(10). PMC: 5923084. DOI: 10.1128/JVI.02181-17. View

10.

Lin Y, Wang K, Lei H, Lin Y, Yeh T, Liu H . Virus replication and cytokine production in dengue virus-infected human B lymphocytes. J Virol. 2002; 76(23):12242-9. PMC: 136880. DOI: 10.1128/jvi.76.23.12242-12249.2002. View

11.

Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

12.

Sung J, Lee C, Wu-Hsieh B . Intrahepatic infiltrating NK and CD8 T cells cause liver cell death in different phases of dengue virus infection. PLoS One. 2012; 7(9):e46292. PMC: 3458800. DOI: 10.1371/journal.pone.0046292. View

13.

Lauring A, Jones J, Andino R . Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol. 2010; 28(6):573-9. PMC: 2883798. DOI: 10.1038/nbt.1635. View

14.

Lai C, Williams K, Wu Y, Knight S, Balmaseda A, Harris E . Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis. 2013; 7(9):e2451. PMC: 3777924. DOI: 10.1371/journal.pntd.0002451. View

15.

Halstead S . Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med. 1970; 42(5):350-62. PMC: 2591710. View

16.

Cruz-Oliveira C, Freire J, Conceicao T, Higa L, Castanho M, Da Poian A . Receptors and routes of dengue virus entry into the host cells. FEMS Microbiol Rev. 2015; 39(2):155-70. DOI: 10.1093/femsre/fuu004. View

17.

Park J, Cha J, Choi K, Lee K, Han K, Jang Y . Fucoidan inhibits LPS-induced inflammation in vitro and during the acute response in vivo. Int Immunopharmacol. 2016; 43:91-98. DOI: 10.1016/j.intimp.2016.12.006. View

18.

Pierson T, Diamond M . A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection. Prog Mol Biol Transl Sci. 2015; 129:141-66. PMC: 4910618. DOI: 10.1016/bs.pmbts.2014.10.005. View

19.

Bhatt S, Gething P, Brady O, Messina J, Farlow A, Moyes C . The global distribution and burden of dengue. Nature. 2013; 496(7446):504-7. PMC: 3651993. DOI: 10.1038/nature12060. View

20.

Slon Campos J, Mongkolsapaya J, Screaton G . The immune response against flaviviruses. Nat Immunol. 2018; 19(11):1189-1198. DOI: 10.1038/s41590-018-0210-3. View